24/7 Customer Support
The dental bone graft and substitutes market in Europe is expected to grow to US$ 435.66 Mn by 2030. With an estimated compounded annual growth rate of 6.9%, the market is analyzed to see a jump of 55% over the forecast period 2022-2030. The market for bone grafts and substitutes was valued at US$ 243.31 Mn in 2021.
In Europe, the incidence of oral cancer ranges from 5 to 10 cases per 100,000 people, according to the World Health Organization (WHO) (GLOBOCAN project). The prevalence of oral cancer is relatively higher in men, in older people, and among people of low education and low income. Around 20% of adults and more than 30% of seniors have advanced periodontal disease. Moreover, according to the Journal of the American Medical Association, from March to August 2020, the rate of weekly visits to a dentist was lower than in 2019.
End-users like hospitals and clinics have reported a decrease in patient visits as a result of the global lockdown limitations. Elective procedures were postponed or canceled during the COVID-19 pandemic, and the majority of elective surgeries were postponed or canceled. As a result, demand for oral/ dental surgery products such as bone grafts and substitutes has dropped dramatically. In addition, protracted factory closures by market players in several countries hindered device production. The majority of industries are having difficulty finding human resources to manufacture bone grafts and substitutes at manufacturing sites.
The dental bone grafts add volume and density to the jaw in areas where bone loss has occurred or where there is insufficient bone density. An increase in focus on R&D activities in bone grafts & their substitutes creates a lucrative growth opportunity for the market. Regulatory restrictions regarding the use of allograft materials have driven a shift towards the use of more synthetic grafting materials. Bone grafts are commonly used in dental surgeries and in dental implant procedures.
Prominent factors influencing market growth during the forecast period include:
Development of Biocompatible Synthetic Bone Grafts
Synthetic bone grafts are a viable alternative to autologous and allogeneic grafts due to their widespread availability, low cost, gradual biodegradation, higher compression strength, and lack of donor-site morbidity and virus transmission hazards. Calcium phosphate-based biomaterials and recombinant human bone morphological proteins are the most extensively utilized synthetic bone substitutes and biological factors. The development of biocompatible synthetic bone grafts is mainly due to an increase in demand for dental bone grafts in the market.
Increase in Demand for Dental Bone Grafts
The most prevalent application of bone grafting is in the placement of dental implants to repair a lost tooth's edentulous region. Bone grafts are expected to be used in around half of all dental implant operations currently conducted. Around 2.2 million bone graft surgeries are conducted globally each year, costing US$ 664 million by 2021. In Germany, there is a long-established insurance-based healthcare system of ‘sick funds’, which are not-for-profit organizations. Almost, 90% of the population belongs to one of these funds. The number of surgical procedures for treating bony defects is expected to climb approximately 13% yearly. However, the market is not free from hindrances.
Ethical Issues Related to Bone Grafting Procedures
Patients’ thoughts about the various bone graft materials available or their willingness to use these biomaterials in their procedures hamper the growth. Also, due to religious, ethical, and cultural reasons, the source of the bone graft may be undesirable to the patient. The bone transplants that generated the highest refusal percentage among respondents were allografts as 41% population declared that they would never accept this type of bone graft or would only do so if it was very necessary. However, though bone grafting has been a popular procedure across the globe, its high cost is one of the obstacles faced by the players in the market.
Higher Costs of Surgeries
Grafting surgery is one of the expensive treatments as multiple surgical procedures are needed. As per studies, this surgery is safe as bone tissue is extracted straight from various regions of the patient's body. The average cost of a dental bone graft ranges from $300 to $3,000 per graft.
Key Takeaways from the Report based on Segments
The cumulative share of the major players is close to 52% in 2021. The key players in the Europe dental bone grafts and substitutes market are Ivoclar Vivadent, Zimmer Biomet, Dentsply Sirona, Nobel Biocare, Medtronic, BioHorizons IPH, Inc., ACE Surgical Supply Company, Geisclich Pharma AG, and Straumann Group among others. Through extensive research, it is found that big players have adopted various competitive strategies such as mergers & acquisitions in order to have a grip on an emerging market. Furthermore, leading companies are expanding their geographical boundaries by acquiring small brands and domestic companies.
Recent Developments by Key Players
Europe dental bone grafts and substitutes market is segmented based on product, treatment type, application, end-user, and region. The industry trends in the market are sub-divided into different categories in order to get a holistic view of the Europe marketplace.
Following are the different segments of the Europe dental bone grafts and substitutes market:
By Product segment
By Treatment Type segment
By Application segment
By End User segment
By Country segment
|Market Size Value in 2021||US$ 243.31 Million|
|Expected Revenue in 2030||US$ 435.66 Million|
|Unit||Value (USD Mn)|
|Segments covered||By Product, By Treatment, By Application, By End-User, By Region|
|Key Companies||Ivoclar Vivadent, Zimmer Biomet, Dentsply Sirona, Nobel Biocare, Medtronic, BioHorizons IPH, Inc., ACE Surgical Supply Company, Geisclich Pharma AG, and Straumann Group among others|
|Customization Scope||Get your customized report as per your preference. Ask for customization|
Bone grafts are commonly used in dental surgeries and in dental implant procedures.
Xenograft, autograft, allograft, and synthetic analysis are the different types of dental bone grafts.
The Europe dental bone grafts and substitutes market was estimated at US$ 243.31 Million in 2021 and is expected to reach US$ 435.66 Million by 2030.
France held the major share in terms of revenue, in the Europe dental bone grafts and substitutes market in 2021.
Factors such as the development of biocompatible synthetic bone grafts and the increase in demand for dental bone grafts drive the growth in the Europe dental bone grafts and substitutes market.
Higher costs of surgeries and ethical issues related to bone grafting procedures is a restraining factor that inhibits the growth of the market.
The synthetic bone graft substitutes segment is expected to project the highest CAGR over the forecast period.
The clinical applications segment dominated the market in 2021.
Increase in focus on R&D activities in bone grafts & their substitutes creates a lucrative growth opportunity for the market.
Product, treatment type, application, and end-users are the different segments in the Europe dental bone grafts and substitutes market.
The key players operating in the market include Ivoclar Vivadent, Zimmer Biomet, Dentsply Sirona, Nobel Biocare, Medtronic, BioHorizons IPH, Inc., ACE Surgical Supply Company, Geisclich Pharma AG, and Straumann Group among others.